Welcome to our dedicated page for Theratechnologies Common news (Ticker: THTX), a resource for investors and traders seeking the latest updates and insights on Theratechnologies Common stock.
Theratechnologies Inc. (symbol: THTX) is a biopharmaceutical company that markets prescription products across the United States, Europe, and Canada. Founded in 1993 and headquartered in Montreal, Canada, the company is dedicated to addressing the unmet medical needs of patients living with HIV and other serious health conditions.
Core Products:
- EGRIFTA and EGRIFTA SV: These products help reduce excess abdominal fat in HIV-infected patients with lipodystrophy, improving their quality of life.
- Trogarzo: A vital injection treatment for multidrug-resistant HIV-1 infected patients, offering hope to those who have limited treatment options.
Pipeline Products:
- F8 Formulation: A promising treatment for HIV-associated lipodystrophy, currently in development.
- TH-1902: A potential breakthrough in the treatment of triple-negative breast cancer.
- TH-1904: Targeting ovarian cancer, another pipeline product with significant potential.
Theratechnologies generates significant revenue from its relationship with RxCrossroads, a major customer based in the United States. The company's strategic partnerships and innovative products showcase its commitment to improving patient outcomes in serious medical conditions. With a dedicated focus on research and development, Theratechnologies continues to make strides in the biopharmaceutical industry.
Rhea-AI Summary
Theratechnologies reaches agreement with Marathon Asset Management to amend credit agreement, including removal of minimum liquidity covenant and change to adjusted EBITDA target
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.34%
Tags
-
Rhea-AI Summary
Theratechnologies files sBLA for F8 formulation of tesamorelin to FDA for review, which is intended to replace EGRIFTA SV® for treatment of excess abdominal fat in adults with HIV and lipodystrophy. F8 formulation is 8 times more concentrated than EGRIFTA® and 2 times more concentrated than F4 formulation, enabling smaller volume of administration. New formulation is patent protected in the U.S. until 2033.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.34%
Tags
-
Rhea-AI Summary
Theratechnologies CEO to present at Cantor Fitzgerald Global Healthcare Conference 2023 on September 27. CFO also available for investor meetings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.93%
Tags
Rhea-AI Summary
Theratechnologies Inc. to report Q3 financial results on September 26, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.26%
Tags
-
Rhea-AI Summary
Theratechnologies to present at H.C. Wainwright 25th Annual Global Investment Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
28.95%
Tags
-
Rhea-AI Summary
Theratechnologies expects positive adjusted EBITDA for Q3 2023 and holds US$22.9 million in cash, bonds, and money market funds as of August 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.57%
Tags
Rhea-AI Summary
Theratechnologies activates all US-based clinical sites for Phase 1 trial of sudocetaxel zendusortide
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.03%
Tags
-
Rhea-AI Summary
Paul Lévesque, President and CEO of Hamilton Thorne Ltd., shares his Company's story in an interview with TMX Group.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.75%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.85%
Tags
Rhea-AI Summary
Theratechnologies Inc. has entered into an agreement with Marathon Asset Management to amend its credit agreement, lowering the minimum liquidity requirement to $15 million until October 31, 2023. The company is taking steps to ensure compliance with the liquidity covenant.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.85%
Tags
FAQ
What is the current stock price of Theratechnologies Common (THTX)?
The current stock price of Theratechnologies Common (THTX) is $1.76 as of December 23, 2024.
What is the market cap of Theratechnologies Common (THTX)?
The market cap of Theratechnologies Common (THTX) is approximately 84.8M.
What does Theratechnologies Inc. specialize in?
Theratechnologies Inc. specializes in biopharmaceutical solutions for HIV and serious medical conditions like cancer.
Where are Theratechnologies' products marketed?
Theratechnologies markets its products in the United States, Europe, and Canada.
What are the main products offered by Theratechnologies?
The main products include EGRIFTA and EGRIFTA SV for HIV-related lipodystrophy and Trogarzo for multidrug-resistant HIV-1.
What are Theratechnologies' pipeline products?
Pipeline products include the F8 formulation for HIV-associated lipodystrophy, TH-1902 for triple-negative breast cancer, and TH-1904 for ovarian cancer.
When was Theratechnologies Inc. founded?
Theratechnologies Inc. was founded in 1993.
Where is Theratechnologies Inc. headquartered?
Theratechnologies Inc. is headquartered in Montreal, Canada.
Who is a major customer of Theratechnologies?
RxCrossroads, based in the United States, is a major customer of Theratechnologies.
What is the significance of Trogarzo?
Trogarzo is an important treatment for patients with multidrug-resistant HIV-1, providing a crucial option for those with limited alternatives.
How does EGRIFTA benefit HIV patients?
EGRIFTA helps reduce excess abdominal fat in HIV-infected patients with lipodystrophy, improving their health and quality of life.
What is Theratechnologies' approach to innovation?
Theratechnologies focuses on research and development to create innovative treatments for serious medical conditions and improve patient outcomes.
Theratechnologies Inc. Common